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Objective: Sweetening agents have been recommended in position 
statements and consensus documents for procedura l pain manage-
ment in neonates; however, it is not clear if this has resulted in 
widespread adoption in clinical practice. The objective of this study 
was to investigate unit-specific protocols for the use of sweetening 
agents . 
Methods: Structured telephone survey with qualified personnel in 
special care (level II) nurseries and neonatal intensive care (level 
III) units across Canada. The frequency and pattern of recom-
mended use of sweetening agents was documented. 
Results: Eighty-six of 92 units (93.5%) participated. Sixty-four 
percent recommended sucrose and 2.3% recommended glucose for 
procedural pain management; 87.7% had a guideline. Sweetening 
agents were most commonly recommended for venipuncture/ 
venous cannulation (91.2% for both), lumbar puncture (87.7%), 
and heel lance (82.5 % ). Dosing guidelines ranged from 0.05 mL of 
24% sucrose solution to 3 mL of 25% sucrose solution . Sweeteners 
were not recommended for infants with necrotizing enterocolitis 
(77.2%) or those who were nil per os (75%). 
Conclusions: Sweetening agents were recommended for procedural 
pain management in two-thirds of special care nurseries and 
neonatal intensive care units across Canada with extensive 
variability in specific dosing guidelines. Audits of pain management 
practices should therefore account for unit-specific practice guide-
lines. 
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Newborn infants in special care (level II) nurseries and intensive care (level III) units are exposed to many 
painful medical procedures as part of clinical care. 1 Not 
only do these procedures cause acute pain, but when 
performed repeatedly, lead to long-term changes in the 
central nervous system that causes alterations in the 
processing of subsequent painful stimuli. 2•3 As a result, 
pain prevention and management strategies have been 
identified as a priority for this patient population.4 
Dozens of clinical trials have demonstrated analgesic 
effects from sweet-tasting substances such as sucrose when 
administered to newborn infants during painful medical 
procedures. 5 Although not fully understood , the underlying 
mechanism of action is hypothesized to involve activation 
of the endogenous opioid system by sweet taste. 6 Sucrose 
has been the most widely studied of the sweetening agents 
currently in use for the relief of pain, followed by glucose. 
Between 2000 and 2006, several consensus documents and 
position statements by pain researchers and national 
organizations [American Academy of Pediatrics (AAP) 
and Canadian Paediatric Society (CPS)] were published 
recommending routine use of sucrose for the management 
of procedural pain in neonates .4•7- 10 
It is not known if these recommendations have been 
adopted by special care nurseries and neonatal intensive 
care units. In the only previous national survey of neonatal 
unit protocols for analgesia conducted in Australia in 
2004, 11 23% ofunits reported using sucrose or other sweet-
tasting solutions. That study was conducted before pub-
lication of a large systematic review and AAP and CPS 
position statements.5•9 The objective of the present study 
was to determine current practice guidelines for the use of 
sweetening agents in newborn infants undergoing painful 
medical procedures in Canadian special care nurseries and 
neonatal intensive care units. 
MATERIALS AND METHODS 
We conducted a Canada-wide survey of special care 
nurseries and neonatal intensive care units regarding their 
clinical practice guidelines for sweetening agents. Potential 
units were identified from the provincial ministries of health 
for each province. Using a structured telephone interview, a 
trained interviewer questioned the charge nurse, nurse 
educator, or qualified designate in each unit about the use 
of sweet-tasting solutions and unit characteristics (such as 
number of inpatient beds, type of newborn care services 
provided, number of attending physicians). Potential 
respondents were identified by senior investigators (via 
local and national research and clinical networks) or by the 
units themselves (during first telephone contact by the 
interviewer). All respondents verified their qualification to 
answer questions before their participation. The survey was 
designed according to standard survey construction guide-
lines and included mainly closed-ended questions .12 It was 
pretested for clarity and completeness on respondents from 
3 local institutions. The time needed to administer the 
survey was approximately I 0 minutes. For units that used 
sweeteners, respondents mailed or faxed their protocols to 
the investigators to verify responses . The study was 
approved by the ethics boards of the University of Toronto 
and The Hospital for Sick Children. The study was 
explained and verbal consent was obtained from respon-
dents before participation. 
SAMPLE SIZE AND STATISTICAL ANALYSIS 
We estimated a sample size of 100 units, with 23% 
having unit-specific protocols for sweeteners (as per the 
prior survey). 11 This resulted in a precision of approxi-
mately 10%.13 Logistic regression was performed to 
identify factors predictive of sweetening agent utilization, 
including: type of unit; number of inpatient beds; number 
of physicians; presence of a pain committee; presence of 
nurse practitioners; and a pain champion. Categorical data 
were reported as frequency (percent) and continuous data 
were reported as mean (SD) or mode (range). Data were 
analyzed using the statistical software package SPSS 
(v. l5.0, Chicago, IL). A P value of ::; 0.05 was considered 
significant. 
RESULTS 
The study was conducted between June 12, 2007 and 
September 19, 2007. Out of 98 potential units identified by 
the provincial ministries of health, 92 qualified; in excluded 
units, neonatal special care and intensive care services were 
not being provided. In 4 cases, respondents could not be 
reached after multiple attempts, and in 2 cases, respondents 
declined participation. Therefore, interviews were con-
ducted with respondents from 86 (93.5%) units. 
Respondents included 33 unit managers, 19 nurse 
educators, 13 charge nurses, I 0 pain committee members, 6 
nurse practitioners, and I neonatologist. Fifty-two (60.5%) 
units contained special care nurseries, 3 (3.5%) contained 
neonatal intensive care units, and the remaining 31 (36%) 
contained both. The mean (SD) number of inpatient beds 
was 20 (14). 
Overall, 55 (64%) of units had a practice guideline in 
place for the use of sucrose and 2 (2.3%) for another 
sweetener (glucose) . Fifty (87.7%) units with a written 
protocol provided it to investigators. Most of the time, the 
respondent referred to the written protocol when answering 
survey questions. The respondent also qualified any aspect 
of the protocol that was unspecific or unclear. Fifty-two 
(91 .2%) units with guidelines recommended sweetening 
agents for venipuncture/venous cannulation, followed by 50 
(87 .7%) for lumbar puncture and 47 (82.5%) for heel 
lancing, respectively (Table I). In 24 ( 42.1%) units, a 
pacifier was always given with the sweetener. 
The dose for sucrose ranged from 0.05 mL of 24% 
solution to 3 mL of 25% solution. In 80% of the units, 
the sucrose dosage regimen varied according to infant 
gestational age or weight. For infants < 31 weeks' gestation 
or < 1500 g, the most commonly recommended dose was 
0.5 mL of 24% solution, and for ::=:: 31 weeks' gestation or 
TABLE 1. Recommended Use of Sweetening Agents for Different 
Procedures (N =57) 
Procedures 
Venipuncture 
Venous cannulation 
Lumbar puncture 
Heel lance 
Intramuscular injection 
Arterial puncture 
Subcutaneous injection 
Dressing change 
Urinary catheterization 
Suprapubic aspiration 
Eye examination 
Chest tube 
Percutaneous central venous catheter placement 
Nasogastric tube insertion 
Tracheal suctioning 
Endotracheal tube insertion 
No.(%) 
52 (91.2) 
52 (91.2) 
50 (87.7) 
47 (82.5) 
45 (78.9) 
43 (75.4) 
42 (73. 7) 
38 (66. 7) 
36 (63.2) 
34 (59.6) 
33 (57.9) 
32 (56.1) 
32 (56.1) 
13 (22.8) 
8 (14.0) 
3 (5 .3) 
::=:: 1500 g, it was I mL of 24% solution. The guidelines 
restricted the use of sweetening agents to infants of ::=:: 27 to 
28 weeks' gestation in II units, and ::=:: 30 to 32 weeks' 
gestation in 13 units. 
A limit on the maximum number of doses that could 
be administered during a single procedure was present 
in 23 (40.4%) units, and ranged from I to 4 (mode, 1). 
In addition, 42 (73.7%) units reported a maximum daily 
number of doses that ranged from 2 to 24 (mode, 6). 
The most common contraindications for the use of 
sweetening agents included proven/suspected necrotizing 
enterocolitis and nil per os, in 44 (77.2%) and 42 (75%) 
units, respectively (Table 2) . Logistic regression analysis did 
not identify any factors that significantly predicted the 
reported utilization of sweetening agents. 
DISCUSSION 
The present study demonstrated that two-thirds of 
special care nurseries and neonatal intensive care units 
across Canada had clinical practice guidelines that support 
the use of sweetening agents for procedural pain manage-
ment. This rate is almost 3 times higher than a 2004 survey 
in Australia, 11 but falls short of currently published 
consensus guidelines and position statements that recom-
mend use of sweetening agents in all infants undergoing 
procedures. 9 
TABLE 2. Contraindications for Use of Sweetening Agents 
(N =57) 
Characteristic 
Necrotizing enterocolitis 
Nil per os (NPO)* 
Glucose intolerance 
Concurrent opioid use 
Specific gestational age group 
Infant of diabetic mother* 
Parental refusal 
*N ~ 56. 
No.(%) 
44 (77.2) 
42 (75.0) 
21 (36.8) 
21 (36.8) 
18(31.6) 
16 (28.6) 
12 (21.1) 
In addition, the present study determined that the 
dosing regimens for sweeteners were highly variable, and 
restrictions were often placed on the characteristics of 
infants that were eligible to receive them. Thus, the presence 
of a practice guideline did not ensure that all infants were 
eligible to receive sweetening agents before all painful 
medical procedures. 
We hypothesize that the variability in clinical practice 
guidelines is due to gaps in knowledge about the 
pharmacology of sweetening agents, including the mechan-
ism of action, optimal dose, and safety of repeated does.9 
That there is no consensus about what constitutes the 
"appropriate use of sweetening agents" among units has 
implications for the interpretation of pain audits that 
document actual utilization patterns of analgesic agents. 
Pain management audits are usually discussed in terms of 
barriers in knowledge, attitudes, and beliefs. 14 It is clear 
from the results of this study that utilization patterns for 
sweetening agents need to be interpreted within the context 
of acceptable practices in individual units rather than 
externally published consensus statements. 
The strengths of the present study are the very high 
response rate (93.5%) and validation of protocols for 
analgesic use. In contrast, the previous survey achieved a 
relatively low response rate (58%), and did not validate 
responses. 11 We did not measure actual utilization of 
sweetening agents, and therefore cannot comment on the 
proportion of infants given sweetening agents relative to 
guideline recommendations. This is clearly an important 
area for future study. 
In conclusion, this study demonstrated that two-thirds 
of Canadian special care units and neonatal intensive care 
units have practice guidelines in place for the use of 
sweetening agents to manage procedural pain in neonates. 
There are wide variations in prescribing guidelines, result-
ing in the potential for many infants to undergo procedures 
without sweetening agent analgesia. Further study of the 
pharmacology of sweeteners is needed to answer the current 
gaps in research knowledge that will in turn, be used to 
modify and improve practice guidelines. 
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